Lactobacillus paracasei Extracellular Vesicles for Ocular Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective solutions for age-related and inflammatory ocular diseases, particularly those caused by oxidative stress and immune or metabolic dysfunction, with no reported use of Lactobacillus paracasei-derived extracellular vesicles for such conditions.
Innovation Solution
A composition comprising Lactobacillus paracasei-derived extracellular vesicles is developed for preventing or treating ocular diseases, which are administered orally and distributed through the blood-brain barrier to inhibit IL-6 secretion, activate AMPK signaling, and reduce oxidative stress-induced retinal degeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for ocular diseases, then current standard therapies are applied, but they lack effectiveness for age-related and inflammatory ocular diseases caused by oxidative stress and immune dysfunction
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach by using extracellular vesicles (20-200 nm) instead of conventional drugs, enabling oral administration and systemic distribution to the eye. This parameter change resolves the contradiction by providing a delivery mechanism that is both effective and adaptable to various ocular disease types through a single platform.
Solution Approach 2:
The patent introduces extracellular vesicles as an intermediary carrier that mediates the delivery of therapeutic compounds to ocular tissues. These vesicles protect the cargo from degradation, facilitate absorption through the gut barrier, and enable targeted delivery to the eye, thereby improving effectiveness while maintaining versatility across different disease conditions.
2Ease of operation
If bacteria-derived extracellular vesicles are used, then absorption through mucosa is improved, but potential safety concerns arise from using bacterial products
Solution Approach 1:
The patent extracts only the beneficial functional components of bacteria (extracellular vesicles with specific size and membrane properties) while leaving behind the harmful bacterial elements (toxins, cell wall components, genomic DNA). This extraction approach maintains the advantageous absorption characteristics of bacterial vesicles while eliminating safety concerns associated with live bacteria or complete bacterial products.
Solution Approach 2:
The patent uses extracellular vesicles as disposable, non-living therapeutic carriers that can be produced, administered, and eliminated without persistence in the body. These vesicles perform their delivery function and are then naturally degraded, avoiding the safety issues associated with live bacteria that could proliferate or cause infection, while maintaining efficient absorption.
3Reliability
If retinal cells are exposed to oxidative stress, then visual function deteriorates, but the cells lack regenerative capacity due to their post-mitotic nature
Solution Approach 1:
The patent applies preliminary protective action by administering extracellular vesicles before oxidative stress causes irreversible damage. The vesicles deliver protective compounds (antioxidants, anti-inflammatory agents) in advance, enabling retinal cells to resist oxidative stress and prevent dysfunction rather than attempting regeneration after damage occurs. This preliminary protection approach is particularly suited for post-mitotic cells that cannot regenerate.
Solution Approach 2:
The patent converts harmful oxidative stress into a beneficial therapeutic opportunity by using the same stress pathways that damage retinal cells as targets for intervention. The extracellular vesicles deliver compounds that specifically counteract oxidative stress mechanisms, transforming the harmful environment into a context where targeted therapy can protect and maintain visual function in post-mitotic cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vesicles effectively inhibit inflammatory responses, enhance metabolic function, and significantly reduce retinal degeneration in ocular disease models, demonstrating potential as a therapeutic agent for age-related and inflammatory ocular diseases.
Implementation Method 1
bacteria-derived extracellular vesicles have a size of approximately 20 to 200 nanometers, and thus relatively freely pass through epithelial cells via the mucosa to be absorbed in our bodies
Implementation Method 2
after being absorbed into cells, effectively inhibit the secretion of IL-6, which is the main mediator of intractable inflammatory diseases
Implementation Method 3
activate AMPK signaling to increase metabolic function, and efficiently inhibit the occurrence of an ocular disease caused by cell senescence and inflammation
Data Source
AI summary
The claimed subject matter relates to Lactobacillus paracasei-derived extracellular vesicles and a use thereof, and more particularly, to a composition for alleviating, preventing and treating an ocular disease, which includes Lactobacillus paracasei-derived extracellular vesicles as an active ingredient, capable of effectively inhibiting the occurrence of an ocular disease caused by oxidative stress-mediated cell senescence.